USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Regulatory and Infrastructure Reforms in India and China Catalyzing the Asian Specialty Generics Market
Regulatory and Infrastructure Reforms in India and China Catalyzing the Asian Specialty Generics Market
High Unmet Needs in Niche Oncology Indications will Drive Future Growth Potential
19-Feb-2021
North America
Market Research
Frost & Sullivan’s Transformational Health team provides critical insights into the Asian specialty generics market with this research service, highlighting growth opportunities, selected countries’ biopharmaceutical environment, and significant R&D, regulatory, and infrastructure reforms influencing its growth. The report examines similarities and contrasts between various Asian countries in specialty generics R&D, manufacturing, adoption, and access.
Specialty generics do not have a commonly accepted definition, often used interchangeably as complex generics. Specialty pharmaceuticals are often large, injectable, protein-based molecules produced through a biotechnology process. But they may also be small molecules produced through traditional pharmaceutical manufacturing methods.
Specialty generics offer lucrative market opportunities to Asian drug manufacturers to increase profit margins by developing innovative, value-added alternatives of existing drugs to offset traditional generics' shrinking margins in developed countries. The focus on improving the R&D landscape, especially for biologics, will attract global biopharmaceuticals to Asia due to the inherent advantage of a large patient pool and low-cost development and manufacturing.
This report reviews drivers propelling specialty generics adoption in these countries. For example, the rising prevalence of chronic diseases such as diabetes and cancer, where specialty drugs primarily drive treatment, will drive the demand for economic and easy-to-administer generic formulations to improve access. Self?administered medications using new drug delivery systems such as nasal sprays, autoinjectors, pen injectors, prefilled syringes, and needle-free injectors offer convenience that will drive the specialty generics demand. Specialty generics development provides competitive differentiation to companies compared to traditional generics. Compared to the 505(b)(1) pathway for new drug approval (NDA), the 505(b)(2) pathway in the US offers faster approval, lower risk, and market exclusivity from 3 to 7 years in some instances when coupled with the correct development and regulatory strategies.
Research Highlights
The report highlights biopharmaceutical industry dynamics in selected countries. China is the most attractive site due to its strong focus on developing R&D infrastructure and capabilities specifically for biologics. India is the most lucrative location for low-cost manufacturing. Generics participants in India are increasingly focusing on developing innovative products, although the country lags in macroeconomic indicators due to low healthcare spending. Singapore and Hong Kong have a conducive macroeconomic and biopharma environment, followed by Thailand. While the market is nascent, there are signs that strong growth and new regulatory and infrastructure reforms are ahead, and this report will outline and provide commentary regarding those signs.
Author: Surbhi Gupta
Why is it Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top Three Strategic Imperatives on the Asian Specialty Generics Market
Growth Opportunities Fuel the Growth Pipeline Engine™
Executive Summary—Specialty Generics Market
Key Growth Opportunities—The Asian Specialty Generics Market
Specialty Generics Market Scope of Analysis
Specialty Generics Market Segmentation
New Drug Application Regulatory Pathways in the US—Specialty Generics Market
Potential Regional Biopharma Players for Strategic Partnerships—Specialty Generics Market
Potential Regional Biopharma Players for Strategic Partnerships—Specialty Generics Market (continued)
Growth Drivers for the Specialty Generics Market
Growth Restraints for the Specialty Generics Market
Specialty Drugs Share in Overall Drugs Spending—Specialty Generics Market
Selected Countries’ Market Attractiveness—Specialty Generics Market
Biopharmaceutical Market Landscape in Selected Asian Countries—Specialty Generics Market
Biopharmaceutical Market Landscape in Selected ASEAN Countries—Specialty Generics Market
Biopharmaceutical Industry Readiness (India and China)—Specialty Generics Market
Biopharmaceutical Industry Readiness (Singapore and Hong Kong)—Specialty Generics Market
Biopharmaceutical Industry Readiness (Emerging ASEAN Countries)—Specialty Generics Market
Growth Opportunity 1: Small and Mid-Sized Players Developing Expertise in Niche Oncology Indications
Growth Opportunity 1: Small and Mid-Sized Players Developing Expertise in Niche Oncology Indications (continued)
Case Study—Developing Drugs for Niche Oncology Indications and Orphan Diseases with High Unmet Needs
Growth Opportunity 2: Wearable, Long-Acting Combination Products for Complex Diseases
Growth Opportunity 2: Wearable, Long-Acting Combination Products for Complex Diseases (continued)
Case Study—Improving Patient Care and Reducing Healthcare Costs Through Innovative Drug-device Combinations
Growth Opportunity 3: Korean Companies’ Strategic Collaborations for Leveraging the 505(b)(2) Pathway
Growth Opportunity 3: Korean Companies’ Strategic Collaborations for Leveraging the 505(b)(2) Pathway (continued)
Case Study—Korean Companies Should Focus on Global Markets and Leverage Their Specialty Generics Capabilities
List of Exhibits
Legal Disclaimer
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
Research Highlights
The report highlights biopharmaceutical industry dynamics in selected countries. China is the most attractive site due to its strong focus on developing R&D infrastructure and capabilities specifically for biologics. India is the most lucrative location for low-cost manufacturing. Generics participants in India are increasingly focusing on developing innovative products, although the country lags in macroeconomic indicators due to low healthcare spending. Singapore and Hong Kong have a conducive macroeconomic and biopharma environment, followed by Thailand. While the market is nascent, there are signs that strong growth and new regulatory and infrastructure reforms are ahead, and this report will outline and provide commentary regarding those signs.
Author: Surbhi Gupta
| Deliverable Type | Market Research |
|---|---|
| No Index | No |
| Podcast | No |
| Author | Surbhi Gupta |
| Industries | Healthcare |
| WIP Number | PBA0-01-00-00-00 |
| Is Prebook | No |
| GPS Codes | 9600-B1,99C1-B1,9568-B1,9611-B1 |